Monika Simmons

Summary

Affiliation: Naval Medical Center
Country: USA

Publications

  1. ncbi request reprint An immunocytometric assay based on dengue infection via DC-SIGN permits rapid measurement of anti-dengue neutralizing antibodies
    Nicole C Martin
    Naval Medical Research Center, 503 Robert Grant Avenue, Silver Spring, MD 20910, USA
    J Virol Methods 134:74-85. 2006
  2. pmc Potential role for Toll-like receptor 4 in mediating Escherichia coli maltose-binding protein activation of dendritic cells
    Stefan Fernandez
    Department of Virus Diseases, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA
    Infect Immun 75:1359-63. 2007
  3. ncbi request reprint Short report: Antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine
    M Simmons
    Virology Program, Naval Medical Research Center, Silver Spring, Maryland 20910 7500, USA
    Am J Trop Med Hyg 65:159-61. 2001
  4. pmc Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques
    Monika Simmons
    Viral Diseases Department, Naval Medical Research Center, Silver Spring, MD 20910 7500, USA
    J Virol 80:9577-85. 2006
  5. ncbi request reprint Needle-free Biojector injection of a dengue virus type 1 DNA vaccine with human immunostimulatory sequences and the GM-CSF gene increases immunogenicity and protection from virus challenge in Aotus monkeys
    Kanakatte Raviprakash
    Viral Diseases Department, Naval Medical Research Center, Silver Spring, MD 20910, USA
    Virology 315:345-52. 2003
  6. doi request reprint Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy
    Monika Simmons
    Viral and Rickettsial Diseases Department, Naval Medical Research Center, Silver Spring, MD 20910, USA
    Virology 396:280-8. 2010
  7. ncbi request reprint Variable susceptibility of the owl monkey (Aotus nancymae) to four serotypes of dengue virus
    Ann M Schiavetta
    Walter Reed Army Institute of Research Naval Medical Research Center, 53 Robert Grant Avenue, Silver Spring, Maryland 20910 7500, USA
    Contemp Top Lab Anim Sci 42:12-20. 2003
  8. doi request reprint Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial
    Charmagne G Beckett
    Naval Medical Research Center, Viral and Rickettsial Diseases Department, Infectious Diseases Directorate, Silver Spring, MD, USA
    Vaccine 29:960-8. 2011

Detail Information

Publications8

  1. ncbi request reprint An immunocytometric assay based on dengue infection via DC-SIGN permits rapid measurement of anti-dengue neutralizing antibodies
    Nicole C Martin
    Naval Medical Research Center, 503 Robert Grant Avenue, Silver Spring, MD 20910, USA
    J Virol Methods 134:74-85. 2006
    ..Importantly, serotype-specific neutralizing activity against recently isolated dengue strains with less heterotypic cross-neutralization than laboratory adapted viruses was also demonstrated...
  2. pmc Potential role for Toll-like receptor 4 in mediating Escherichia coli maltose-binding protein activation of dendritic cells
    Stefan Fernandez
    Department of Virus Diseases, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA
    Infect Immun 75:1359-63. 2007
    ..These results provide insight into a mechanism by which MBP might enhance immune responses to vaccine fusion proteins...
  3. ncbi request reprint Short report: Antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine
    M Simmons
    Virology Program, Naval Medical Research Center, Silver Spring, Maryland 20910 7500, USA
    Am J Trop Med Hyg 65:159-61. 2001
    ....
  4. pmc Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques
    Monika Simmons
    Viral Diseases Department, Naval Medical Research Center, Silver Spring, MD 20910 7500, USA
    J Virol 80:9577-85. 2006
    ..5 days), which also showed the highest antibody concentration, including antibodies to NS1, and highest antibody avidity at the time of challenge...
  5. ncbi request reprint Needle-free Biojector injection of a dengue virus type 1 DNA vaccine with human immunostimulatory sequences and the GM-CSF gene increases immunogenicity and protection from virus challenge in Aotus monkeys
    Kanakatte Raviprakash
    Viral Diseases Department, Naval Medical Research Center, Silver Spring, MD 20910, USA
    Virology 315:345-52. 2003
    ..This is a significant improvement compared to our previous study in which one of three monkeys (33%) receiving just the DIME vaccine was completely protected from viremia at 6 months after immunization...
  6. doi request reprint Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy
    Monika Simmons
    Viral and Rickettsial Diseases Department, Naval Medical Research Center, Silver Spring, MD 20910, USA
    Virology 396:280-8. 2010
    ..After challenge with each one of the four DENV serotypes, vaccinated animals exhibited no viremia but showed anamnestic antibody responses to the challenge viruses...
  7. ncbi request reprint Variable susceptibility of the owl monkey (Aotus nancymae) to four serotypes of dengue virus
    Ann M Schiavetta
    Walter Reed Army Institute of Research Naval Medical Research Center, 53 Robert Grant Avenue, Silver Spring, Maryland 20910 7500, USA
    Contemp Top Lab Anim Sci 42:12-20. 2003
    ..Aotus can be an affordable and safe model for testing dengue vaccine efficacy; further testing with higher doses of dengue-2, -3 and -4 viruses is warranted...
  8. doi request reprint Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial
    Charmagne G Beckett
    Naval Medical Research Center, Viral and Rickettsial Diseases Department, Infectious Diseases Directorate, Silver Spring, MD, USA
    Vaccine 29:960-8. 2011
    ..The safety profile of the DENV-1 DNA vaccine is acceptable at both doses administered in the study. These results demonstrate a favorable reactogenicity and safety profile of the first in human evaluation of a DENV-1 DNA vaccine...